IntelGenx Technologies (OTCMKTS: IGXT) has an Important Drug Trial Soon


IntelGenx Technologies (OTCMKTS: IGXT) is a microcap biotech that is starting to see some bullish rips. The stock has appreciated 34% since the beginning of June. As we wrote about in our last piece, IGXT is a company that has the technology to take drugs and put them into dissolvable film form. The film has the benefit of fast absorption and eliminates the fear of swallowing pills, which is an issue for some people.

Shares of IGXT are currently trading at 0.97, giving the company a total market capitalization of $82.63 million. Over a 52-week period, shares of IGXT have traded as low as $0.45 and as high as $1.09.

IntelGenx Technologies (OTCMKTS: IGXT) lead product right now, Tadalafil, is a film-based version of Cialis, the popular drug for treating erectile dysfunction. According to IGXT, Tadalafil is a complete bioequivalent, so it’s really a matter of how you’d prefer to use it – as a film or as a tablet. And IGXT is convinced men would rather use a film-based product rather than a tablet.

Find out when $IGXT stock reaches critical levels. Subscribe to Right Now by entering your Email in the box below.

In addition, IGXT has a phase II proof of concept study set to start soon. Originally slated for the first quarter, July is most likely the month this will start. It’s a Montelukast film product trial, a product that already performed well in early stage trials, and that will seek to underpin an application for approval in a degenerative brain disease indication – a billion dollar market with an incredible degree of unmet need right now.

And there could be plenty more products on the way from IGXT. The company has three different drug delivery platform technologies: VersaFilm (an oral film technology), VersaTab (a multi-layer tablet technology) and AdVersa (a muco-adhesive tablet technology).

Right now, IGXT is working on the development and commercialization of a cannabinoid painkiller, as well as a generic drug related to the central nervous system.

The company did just receive a patent for its oral film technology, which is extremely important for the long-term value of the company. IGXT’s new patented oral film technology allows the instant hydration and complete disintegration of a film in the oral cavity, potentially enabling the active ingredient to become immediately available for enhanced buccal and/or sublingual absorption. In addition, the novel oral film dosage form is applicable for reduced absorption through the gastrointestinal route.

Here are some important passages from the recent press:

IGXT improved delivery systems for solubilizing and stabilizing pharmaceutically active ingredients exhibit enhanced stability derived from the use of a combination of crystallization inhibitors, which together can maintain the active ingredient in a desired plurality of particles in an effective size range within a polymeric film matrix.

This oral dosage form technology patent has broad applicability in film formulation and could be applicable to several current and future projects.

“The granting of this notice of allowance for our novel oral film dosage form validates the innovative work carried out by our talented R&D team, which continues to break new ground in the development of oral film technology,” said Horst G. Zerbe, CEO of IGXT.

“Our rapidly expanding intellectual property portfolio ensures long-term market exclusivity of our products, which is critically important to IntelGenx’ business success. We currently have several additional patent applications pending at the USPTO in relation to oral dosage forms and their method of manufacture, and expect to file for additional patent protection as our research and development continues.”

IntelGenx Technologies (OTCMKTS: IGXT) has some way to go before their technology catches on, and, of course, there is the prospect that it does not. However, the potential here is interesting and this company needs to be watched. Tadalafil could be a huge win for the company, and once it hits the U.S. market in 2018, could provide a huge impact to the company’s top and bottom lines. If you’re willing to accept the company’s risk/reward profile, this could be a unique opportunity to buy low and sell high. For continuing coverage on shares of $IGXT stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!


Please enter your comment!
Please enter your name here